Last reviewed 2026-04-23 · How we verify

HOE140 Icatibant

Icatibant is a selective bradykinin B2 receptor antagonist that blocks the inflammatory effects of bradykinin, a key mediator of angioedema.

Icatibant is a selective bradykinin B2 receptor antagonist that blocks the inflammatory effects of bradykinin, a key mediator of angioedema. Used for Hereditary angioedema (HAE) acute attack treatment, Angioedema prevention in HAE patients.

At a glance

Mechanism of action

Bradykinin is a potent inflammatory peptide that increases vascular permeability and causes swelling. By competitively blocking the B2 receptor on endothelial and smooth muscle cells, icatibant prevents bradykinin-induced vasodilation and plasma extravasation. This mechanism is particularly relevant in hereditary angioedema (HAE), where dysregulation of the contact system leads to excessive bradykinin production.

Approved indications

• Hereditary angioedema (HAE) acute attack treatment
• Angioedema prevention in HAE patients

Common side effects

• Injection site reactions
• Headache
• Nausea
• Diarrhea

Key clinical trials

• I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
• A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
• A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
• A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema (PHASE4)
• A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
• Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 (PHASE4)
• FIRAZYR General Drug Use-Results Survey (Japan)
• A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.